Companies / Kuwait
Hikma - In Favour, But In Debt
January 2008 | Company News AlertIn October 2007 BMI reported on Jordanian drugmaker Hikma Pharmaceuticals' bid for local rival Arab Pharmaceutical Manufacturing Company (APM). December 2007 saw the bid accepted; however, the cost to Hikma was a heavy burden of debt, as the US$163.6 deal was financed largely through borrowings. The APM move ended a busy two years for Hikma, which has seen the acquisitions of Egypt's Alkan Pharma and Germany's Riboserpharm and the purchase of the outstanding 52.5% stake in Saudi Arabian subsidiary Al Jazeera Pharmaceuticals Industries
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
